Novo Nordisk A/S (NYSE:NVO) Shares Bought by McKinley Carter Wealth Services Inc.

McKinley Carter Wealth Services Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 64,424 shares of the company’s stock after acquiring an additional 1,797 shares during the quarter. McKinley Carter Wealth Services Inc.’s holdings in Novo Nordisk A/S were worth $5,542,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NVO. Strategic Investment Solutions Inc. IL purchased a new position in shares of Novo Nordisk A/S during the 2nd quarter valued at approximately $25,000. Daiwa Securities Group Inc. acquired a new stake in Novo Nordisk A/S in the third quarter valued at $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S during the 3rd quarter valued at $42,000. Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S during the 3rd quarter worth $48,000. Finally, M&R Capital Management Inc. increased its position in shares of Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after purchasing an additional 297 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Down 2.9 %

Shares of Novo Nordisk A/S stock opened at $85.00 on Wednesday. The stock has a market capitalization of $381.45 billion, a price-to-earnings ratio of 27.51, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The business’s 50 day simple moving average is $94.75 and its 200-day simple moving average is $114.02.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.